Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients

Therapeutic Drug Monitoring

Volumn 33, Issue 5, 2011, Pages 573-582

  Aspiroz, Elena López ^a   Buelga, Dolores Santos ^b   Figueroa, Salvador Cabrera ^a,c   Galera, Rosa María López ^d   Pascuet, Esteban Ribera ^e   Hurlé, Alfonso Domínguez Gil ^a,b   García Sánchez, María José ^b  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

HIV1; lopinavir; NONMEM; patients; ritonavir; therapeutic drug monitoring

Indexed keywords

ATAZANAVIR; BILIRUBIN; EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; MELTREX; SAQUINAVIR; TENOFOVIR; UNCLASSIFIED DRUG;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY HEIGHT; BODY MASS; BODY WEIGHT; COMPUTER PROGRAM; CONTROLLED STUDY; DEMOGRAPHY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG FORMULATION; DRUG MONITORING; FEMALE; HEPATITIS C VIRUS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; MIXED INFECTION; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL; STEADY STATE;

ADULT; ANTI-HIV AGENTS; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; RITONAVIR;

EID: 80053562468     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31822d578b     Document Type: Article

References (76)

1. Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-näve patients: 4 year follow-up study. AIDS. 2004;18:775-779. (Pubitemid 38535005)
2. Walmsley S, Bernstein B, King M, et al. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346:2039-2046. (Pubitemid 34680595)
3. Benson CA, Deeks SG, Brun SC, et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis. 2002;185:599-607. (Pubitemid 34171464)
4. Kempf DJ, Isaacson JD, King MS, et al. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-174. (Pubitemid 36427141)
5. Von Hentig N. Lopinavir/ritonavir: appraisal of its use in HIV therapy. Drugs Today. 2007;43:221-247. (Pubitemid 47177209)
6. Sham HL, Kempf DL, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998;42:3218-3224. (Pubitemid 28553744)
7. Olson DP, Scadden DT, D'Aquila RT, et al. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS. 2002;16:1743-1747.
8. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother. 1997;41:654-660. (Pubitemid 27098420)
9. Cooper CL, van Heeswijk RPG, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003; 36:1585-1592. (Pubitemid 36783344)
10. Jiménez-Nácher I, Garća B, Barreiro P, et al. Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. J Antimicrob Chemother. 2008;62:816-822.
11. Product monograph Kaletra, lopinavir/ritonavir. North Chicago, IL: Abbott Laboratories; 2001.
12. Klein CE, Chiu YL, Awni W, et al. The tablet formulation of lopinavir/ritonavir provides similar bioavailability to the soft-gelatin capsule formulation with less pharmacokinetic variability and diminished food effect. J Acquir Immune Defic Syndr. 2007;44:401-410. (Pubitemid 46555374)
13. Masquelier B, Breilh D, Neau D, et al. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir containing therapy in protease inhibitorexperienced patients. Antimicrob Agents Chemother. 2002;46:2926-2932.
14. Sadler BM, Gillotin CG, Lou Y, et al. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple dosing. Antimicrob Agents Chemother. 2001; 45:30-37. (Pubitemid 32039089)
15. Dumon C, Solas C, Thuret I, et al. Relationship between efficacy, tolerance, and plasma drug concentration of ritonavir in children with advanced HIV infection. Ther Drug Monit. 2000;22:402-408. (Pubitemid 30622111)
16. Burger DM, Hungen PWH, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80. (Pubitemid 36139829)
17. Gutierrez F, Padilla S, Navarro A, et al. Lopinavir plasma concentrations and changes in lipid levels during salvage therapy with lopinavir/ritonavir containing regimens. J Acquir Immune Defic Syndr. 2003;33:594-600. (Pubitemid 36975846)
18. Van der Leur MR, Burger DM, la Porte C, et al. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006;28:650-653. (Pubitemid 44564064)
19. Department of Health and Human Services (homepage on the Internet). Panel on antiretroviral guidelines for adults and adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents (last review January 10, 2011). Available at: http://aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Accessed February 15, 2011.
20. Johnson MA, Gathe JC, Podzamczer D, et al. A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimen. J Acquir Immune Defic Syndr. 2006;43:153-160. (Pubitemid 44454808)
21. Gazzard B, Bernard AF, Boffito M, et al. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006). HIV Med. 2006;7:487-503. (Pubitemid 44742349)
22. Gonzalez de Requena D, Blanco F, Garcia-Benayas T, et al. Correlation between lopinavir plasma levels and lipid abnormalities in patients taking lopinavir/ritonavir. AIDS Patient Care STDS. 2003;17:443-445. (Pubitemid 37205697)
23. Back D, Gibbons S, Khoo S, et al. An update on therapeutic drug monitoring for antiretroviral drugs. Ther Drug Monit. 2006;28:468-473. (Pubitemid 44314939)
24. Bossi P, Peytavin G, Ait-Mohand H, et al. GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy. HIV Med. 2004;5:352-359. (Pubitemid 39276333)
25. Clevenbergh P, Garraffo R, Durant J, et al. PharmAdapt: a randomized prospective study to evaluate the benefit of therapeutic monitoring of protease inhibitors: 12 week results. AIDS. 2002;16:2311-2315. (Pubitemid 35449017)
26. Khoo SH, Lloyd J, Dalton M, et al. Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)-a randomized controlled trial of therapeutic drug monitoring and adherence support. J Acquir Immune Defic Syndr. 2006;41: 461-467.
27. Torti C, Quiros-Roldan E, Regazzi M, et al. A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study. Clin Infect Dis. 2005;40: 1828-1836. (Pubitemid 40799955)
28. Demeter LM, Jiang H, Mukherjee AL, et al. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviralexperienced, HIV-1-infected patients. AIDS. 2009;23:357-368.
29. Moltó J, Barbanoj MJ, Miranda C, et al. Simultaneous population pharmacokinetic model for lopinavir and ritonavir in HIV-infected adults. Clin Pharmacokinet. 2008;47:681-692.
30. Crommentuyn KML, Kappelhoff BS, Mulder JW, et al. Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005;60:378-389. (Pubitemid 41428469)
31. Bouillon-Pichault M, Jullien V, Azria E, et al. A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-näve and-experienced patients. Antivir Ther. 2009;14:923-929.
32. Lubomirov R, Iulio J, Fayet A, et al. ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics. 2010;20:217-230.
33. Kappelhoff BS, Huitema ADR, Crommentuyn KML, et al. Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients. Br J Clin Pharmacol. 2004;59:174-182. (Pubitemid 40208853)
34. Institut d'Investigacions Biomèdiques August Pi i Sunyer, Institut Cĺnic de Medicina I Dermatoloǵa. Interacciones HIV.com. Available at: http://www.interaccioneshiv.com. Accessed January 25, 2010.
35. Knobel H, Alonso J, Casado JL, et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study. AIDS. 2002;16:605-613. (Pubitemid 34218856)
36. Csajka C, Marzolini C, Fattinger K, et al. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther. 2003;73:20-30. (Pubitemid 36158483)
37. Colombo S, Guignard N, Marzolini C, et al. Determination of the new HIV-protease inhibitor atazanavir by liquid chromatography after solidphase extraction. J Chromatogr B Analyt Technol Biomed Life Sci. 2004; 810:25-34. (Pubitemid 39195020)
38. Beal SL, Sheiner LB, Boeckmann AJ. NONMEM Users Guides. Ellicott City, MD: Icon Development Solutions; 1989-2008.
39. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed. 1999;58:51-64. (Pubitemid 29049052)
40. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm. 1981;9:503-512.
41. Vozeh S, Maitre PO, Stanski DR. Evaluation of population (NONMEM) pharmacokinetic parameter estimates. J Pharmacokinet Biopharm. 1990; 18:161-163.
42. Brendel K, Comets E, Laffont CM, et al. Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide. Pharm Res. 2006;23:2036-2049.
43. Brendel K, Comets E, Laffont CM, et al. Normalized prediction distribution error for the evaluation of nonlinear mixed-models. In: 16 Population Approach Group Europe Meeting; June 13-15, 2007; Copenhagen, Denmark. Abstract 1085.
44. SPSS. SPSS for Windows: Release 10.0.7 User's Manual. Chicago, IL: SPSS; 2000.
45. Colombo S, Buclin T, Cavassini M, et al. Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 2006;50:3801-3808. (Pubitemid 44684896)
46. Solas C, Gagnieu MC, Ravaux I, et al. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients. Ther Drug Monit. 2008;30:670-673.
47. Dickinson L, Boffito M, Back D, et al. Population pharmacokinetics of ritonavir-boosted atazanavir in HIV-infected patients and healthy volunteers. J Antimicrob Chemother. 2009;63:1233-1243.
48. Dailly E, Raffi F, Perré P, et al. Influence of darunavir coadministration on nevirapine pharmacokinetics in HIV-infected patients: a population approach. HIV Med. 2009;10:586-589.
49. Kappelhoff BS, Huitema A, Yalva Z, et al. Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals. Clin Pharmacokinet. 2005;44:849-861. (Pubitemid 41126932)
50. Kappelhoff BS, van Leth F, MacGregor TR, et al. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther. 2005;10:145-155. (Pubitemid 40767640)
51. Cabrera SE, Santos D, Valverde MP, et al. Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemother. 2009;53:2791-2798.
52. Arab-Alameddine M, Iulio J, Buclin T, et al. Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther. 2009;85:485-494.
53. Iulio J, Fayet A, Arab-Alameddine M, et al. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. Pharmacogenet Genomics. 2009;19:300-309.
54. Leyh M, Zipperich S,Winzer R, et al. Pharmacokinetics of lopinavir in the LPV/R-meltrex formulation compared to the LPV/R-soft gelatine capsule in HIV infected patients. Clin Med Ther. 2009;1:697-702.
55. Crommentuyn KML, Mulder JW, Mairuhu ATA, et al. The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients. Antivir Ther. 2004;9:779-785. (Pubitemid 39434342)
56. Oki T, Usami Y, Nakai M, et al. Pharmacokinetics of lopinavir after administration of Kaletra in healthy Japanese volunteers. Biol Pharm Bull. 2004;27:261-265. (Pubitemid 41694714)
57. Boffito M, Else L, Back D, et al. Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther. 2008;13:901-907.
58. Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother. 2004;48:4256-4262. (Pubitemid 39434884)
59. Ofotokun I, Chuck SK, Binongo JN, et al. Lopinavir/ritonavir pharmacokinetic profile: impact of sex and other covariates following a change from twice-daily to once-daily therapy. J Clin Pharmacol. 2007; 47:970-977. (Pubitemid 47094097)
60. Robbins B, Capparelli E, Chadwick E, et al. Pharmacokinetics of high-dose lopinavir-ritonavir with and without saquinavir or nonnucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected pediatric and adolescent patients previously treated with protease inhibitors. Antimicrob Agents Chemother. 2008;52:3276-3283.
61. Burger DM, Muller RJ, van der Leur MR, et al. Lopinavir plasma levels are significantly higher in females. In: Program and Abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy; April 11-13, 2002. Washington, DC. Abstract 6.5.
62. Pham PA, Flexner C, Parsons T, et al. Beneficial pharmacokinetic interaction between atazanavir and lopinavir/ritonavir. J Acquir Immune Defic Syndr. 2007;45:201-205. (Pubitemid 46869813)
63. Barry M, Gibbons S, Back D, et al. Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997;32:194-209. (Pubitemid 27122520)
64. Dailly E, Clotilde A, Raffi F, et al. Pharmacokinetic evidence for the induction of lopinavir metabolism by efavirenz. Br J Clin Phamracol. 2005;60:32-34. (Pubitemid 40942778)
65. StöhrW, Back D, Dunn D, et al. Factors influencing lopinavir and atazanavir plasma concentration. J Antimicrob Chemother. 2010;65:129-137.
66. Solas C, Poizot-Martin I, Drogoul MP, et al. Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor. Br J Clin Pharmacol. 2003;57:436-440. (Pubitemid 38519648)
67. Katende-Kyenda NL, Lubbe MS, Serfontein HP, et al. Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa. J Clin Pharm Ther. 2008;33:393-400.
68. Von Hentig N, Kaykhin P, Stephan C, et al. Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen. Antimicrob Agents Chemother. 2008;52:2273-2275. (Pubitemid 351758578)
69. Flaherty J, Kearney B,Wolf J, et al. A multiple-dose, randomized, crossover, drug interaction study between tenofovir DF and efavirenz, indinavir, or lopinavir/ritonavir. In: 1st IAS Conference on HIV Pathogenesis & Treatment; July 8-11, 2001. Buenos Aires, Argentina. Abstract 336.
70. Kearney BP, Flaherty J,Wolf J, et al. Lack of clinically relevant drug-drug interactions between tenofovir DF and efavirenz, indinavir, lamivudine, and lopinavir/ritonavir in healthy subjects. In: 8th European Conference on Clinical Aspects and Treatment of HIV Infection; October 28-31,2001. Athens, Greece. Abstract P171.
71. Scarsi K, Postelnick M, Murphy R. Comparison of lopinavir/r plasma levels with and without tenofovir as part of HAART in HIV-1 infected patients. In: 5th International Workshop on Clinical Pharmacology of HIV Therapy; April 1-3, 2004; Rome, Italy. Abstract 4.14.
72. Breilh D, Rouzes A, Djabarouti S, et al. Pharmacokinetic drug interaction of lopinavir/ritonavir in combination with tenofovir in experienced HIV+ patients. In: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 30-November 2, 2004; Washington, DC. Abstract A-445.
73. Van der Lugt J, Autar RS, Ubolyam S, et al. Pharmacokinetics and shortterm efficacy of a double-boosted protease inhibitor regimen in treatmentnaive HIV-1-infected adults. J Antimicrob Chemother. 2008;61:1145-1153. (Pubitemid 351524463)
74. Hsu A, Granneman GR, Bertz RJ. Ritonavir. Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet. 1998; 35:275-291. (Pubitemid 28491214)
75. Cameron DW, Japour AJ, Xu Y, et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS. 1999; 13:213-224. (Pubitemid 29050409)
76. Ford J, Boffito M, Maitland D, et al. Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients. J Antimicrob Chemother. 2006;58:1009-1016.